Data Sheet (Cat.No.T6839)

FRAX1036

Chemical Properties



CAS No. : 1432908-05-8

Formula: C28H32ClN7O

Molecular Weight: 518.05

Appearance: no data available

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Biological Description

Description	FRAX-1036 is a effective and selective PAK1 inhibitor.
Targets(IC50)	PAK
In vitro	MDA-MB-175 cells,which are PAK1-amplified (MEK1-S298 and CRAF-S338) ,was observed Potent cellular inhibition at 2.5 to 5 μM concentrations of FRAX1036. PAK1-amplified breast cancer cells are treated with FRAX1036 leading to apoptosis. OVCAR-3 cells are treated with FRAX-1036 resulting in upregulation of p53 and p21, while down-regulating cyclin B1.
In vivo	KT21 are treated with Frax1036 showing slower tumor growth, while Frax1036 is unlikely to have significant blood-brain barrier permeability in mice.
Cell Research	MDA-MB175 cells are treated with increasing concentrations (0, 0.5, 1, 2.5, 5 μM) of FRAX1036 for 24 hours.
Animal Research	Pak2-deficient mice were treated by oral gavage of 30 mg/kg Frax1036.

Solubility Information

Solubility	DMSO: insoluble (< 1 mg/ml refers to the product slightly soluble or insoluble)

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.9303 mL	9.6516 mL	19.3032 mL
5 mM	0.3861 mL	1.9303 mL	3.8606 mL
10 mM	0.193 mL	0.9652 mL	1.9303 mL
50 mM	0.0386 mL	0.193 mL	0.3861 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Ong CC, et al. Breast Cancer Res. 2015, 17:59.
Kosoff RE, et al. Blood. 2015, 125(19):21995-32005.
Alexander B. Koval, et al. Tetrahedron Letters. 2016, 57(3):449-451.
Chow HY, et al. Oncotarget. 2015, 6(4): 1981-1994.